Key Highlights

• In the half-year to 30 June 2026, Neuren reported Royalty income of US$23.3m (A$33.2m), up 29% in US dollars and 17% in Australian dollars on the first half of 2025.

• The policy is a semi-annual payout of 70% to 100% of an "Available Pool", defined as after-tax royalty income less corporate costs.

• Royalties are earned in US dollars but reported in Australian dollars, as the gap between the 29% and 17% growth rates shows.

• Orphan Drug designation applies to medicines for diseases affecting fewer than 200,000 people in the United States.

What does a fresh FDA orphan drug designation mean for Neuren Pharmaceuticals (ASX:NEU), a company already funded by royalties? On 2 November 2026 Neuren announced that the US Food and Drug Administration had granted orphan drug designation to NNZ-2591 for neonatal hypoxic-ischaemic encephalopathy (HIE).

The central development: a fourth orphan indication for NNZ-2591

Orphan drug designation applies to medicines for diseases affecting fewer than 200,000 people in the United States. Benefits include seven years of Marketing exclusivity if the drug is approved, and a Waiver of the prescription drug user fee for a marketing application. Neuren said the designation covers NNZ-2591 (ercanetide), an investigational oral solution, for HIE, a brain injury caused when a newborn's brain receives too little oxygen or blood flow around birth.

The designation does not mean the drug works in HIE, and it does not allow human trials to start. Neuren is running a juvenile animal safety study that the FDA requires before a clinical study in HIE can begin, and it now expects to submit an Investigational New Drug (IND) application in the first half of 2027, previously guided for the fourth quarter of 2026. Chief executive Jon Pilcher called the designation an important commercial milestone and said the company will discuss the development path with the FDA.

All four NNZ-2591 indications, Phelan-McDermid syndrome, Pitt Hopkins syndrome, HIE and Angelman syndrome, now hold orphan designation.

Business model: royalties fund the pipeline

Neuren does not sell DAYBUE itself. It has licensed trofinetide to Acadia Pharmaceuticals, which commercialises it, and Neuren earns tiered royalties. In the half-year to 30 June 2026, Neuren reported royalty income of US$23.3m (A$33.2m), up 29% in US dollars and 17% in Australian dollars on the first half of 2025. Profit after tax was A$4.9m, after Research and Development spending of A$27.4m and corporate costs of A$3.0m, partly offset by A$5.6m of interest income. Cash and short-term investments were A$287m at 30 June 2026.

Acadia's global DAYBUE net sales were US$226m in the first half of 2026, up 25% from US$181m a year earlier. Neuren said about 40% of US patients were receiving DAYBUE STIX, a newer formulation, by 30 June 2026. Acadia's FY2026 global net sales guidance was raised to US$480m to US$510m, and Neuren anticipates FY2026 royalties of US$53m to US$56m. Acadia's longer-term target of US$700m in global net sales for 2028 was reaffirmed. These are licensee and company forecasts, not results.

Dividends and Capital allocation

Neuren's 26 August 2026 half-year announcement introduced its first Dividend programme. The policy is a semi-annual payout of 70% to 100% of an "Available Pool", defined as after-tax royalty income less corporate costs. For the first half the Available Pool was A$21.1m, and the board declared a 15 cent fully franked interim dividend, a 90% payout worth A$19.0m. The ex-dividend date was 15 September 2026, the Record Date 16 September and payment 7 October 2026.

Operating pipeline and upcoming catalysts

The main clinical asset is the Phase 3 Koala trial of NNZ-2591 in Phelan-McDermid syndrome. Neuren said 15 sites in the US and Canada are enrolling, up from two on 1 January 2026, and eight extension sites are active.

In Pitt Hopkins syndrome, an FDA Type B End of Phase 2 meeting was scheduled for late October 2026.

For DAYBUE itself, an EU marketing authorisation has been granted, with a German launch expected in early fourth quarter 2026. In Japan, topline trial results are expected between September and November 2026, with a regulatory submission planned for 2027.

Contingent licence milestones include US$50m after the first calendar year in which North American net sales exceed US$500m, US$35m after the first European commercial sale plus up to US$170m in European sales milestones, and US$15m after first Japanese commercial sale plus up to US$110m in Japanese sales milestones.

Intellectual property and sector position

On 29 September 2026 Neuren announced that the US Patent Office had issued a Notice of Allowance for a weight-banded dosing patent for trofinetide. Neuren said protection is expected to run to 28 March 2041, including six months of paediatric exclusivity, while the existing method-of-use patent expires in July 2036.

Neuren noted that the Rare Pediatric Disease Priority Review Voucher programme has been reauthorised to 30 September 2029, that a voucher sold for US$215m in July 2026, and that Neuren would keep 100% of any voucher earned from an NNZ-2591 approval. That is a possible source of value, not an expectation, as approval is years away and uncertain.

Risks to monitor

Neuren's Earnings depend on a single licensee and a single marketed product. Slower DAYBUE uptake, pricing or reimbursement changes, competition in Rett syndrome, or a shortfall against Acadia's guidance would flow directly into royalties. Clinical risk is concentrated in NNZ-2591: a failed Phase 3 Koala trial would affect the largest pipeline opportunity. HIE has been delayed already by the safety study requirement, and further delays are possible. Royalties are earned in US dollars but reported in Australian dollars, as the gap between the 29% and 17% growth rates shows.

Dates worth watching include the German DAYBUE launch, Japan topline results, the Pitt Hopkins regulatory feedback, Koala enrolment progress, Acadia's fourth-quarter results and Neuren's next dividend decision after the full-year result.